

**Freedom of Information Act 2000**

**The Royal Cornwall Hospitals NHS Trust Response to Information request**

**Date Request Received: 13<sup>th</sup> June 2022**

**FOI Ref No: 16954**

**Requested Information**

Q1) In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib
- Alectinib
- Amivantamab
- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Brigatinib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Durvalumab
- Erlotinib
- Gefitinib
- Lorlatinib
- Mobocertinib
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib
- Pembrolizumab monotherapy
- Pembrolizumab with chemotherapy
- Pemetrexed with Carboplatin/Cisplatin
- Sotorasib
- Tepotinib
- Vinorelbine with Carboplatin/Cisplatin
- Any other active systemic anti-cancer therapy (SACT)
- Palliative care only

Q2) In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Durvalumab
- Nivolumab
- Osimertinib
- Pembrolizumab (Keytruda) Mono
- Pembrolizumab (Keytruda) with Chemotherapy
- Tepotinib
- Other active systemic anti-cancer therapy (SACT)
- Palliative care only

### Response

Q1) From March 2022 to May 2022, the following numbers of patients diagnosed with non-small cell lung cancer (NSCLC) patients (C34.X) were treated with:

- Afatinib **5**
- Alectinib **2**
- Amivantamab **0**
- Atezolizumab monotherapy **16**
- Atezolizumab with chemotherapy **20**
- Brigatinib **2**
- Ceritinib **1**
- Crizotinib **1**
- Dacomitinib **0**
- Dabrafenib with Trametinib **0**
- Durvalumab **6**
- Erlotinib **0**
- Gefitinib **0**
- Lorlatinib **2**
- Mobocertinib **0**
- Nintedanib with Docetaxel **1**
- Nivolumab **0**
- Osimertinib **5**
- Pembrolizumab monotherapy **66**
- Pembrolizumab with chemotherapy **27**
- Pemetrexed with Carboplatin/Cisplatin **18**
- Sotorasib **3**
- Tepotinib **0**

- Vinorelbine with Carboplatin/Cisplatin **0**
- Any other active systemic anti-cancer therapy (SACT):
  - Vinorelbine Monotherapy: **1**
  - Carboplatin with Paclitaxel **3**
  - Carboplatin monotherapy **1**
  - Denosumab monotherapy **12**
  - ECARBO **1**
  - Gemcitabine with Carboplatin **1**
- Palliative care only **13**

Q2) From March 2022 to May 2022, the following numbers patients diagnosed with Squamous non-small cell lung cancer (Sq NSCLC) (Diagnosis code C34.X with morphology 80703) with the following drugs:

- Atezolizumab monotherapy **5**
- Atezolizumab with chemotherapy **0**
- Durvalumab **3**
- Nivolumab **0**
- Osimertinib **0**
- Pembrolizumab (Keytruda) Mono **16**
- Pembrolizumab (Keytruda) with Chemotherapy **11**
- Tepotinib **0**
- Other active systemic anti-cancer therapy (SACT)
  - Carboplatin with Paclitaxel **1**
  - Gemcitabine with Carboplatin **1**
- Palliative care only 2x SCC (plus 3 x adeno, 1 x Small cell and 7 without histo confirmation)

#### Attachment(s)

None

#### Date Response sent:

15<sup>th</sup> June 2022